236 related articles for article (PubMed ID: 21533995)
1. Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.
Müller T; Woitalla D; Muhlack S
Naunyn Schmiedebergs Arch Pharmacol; 2011 Jun; 383(6):627-33. PubMed ID: 21533995
[TBL] [Abstract][Full Text] [Related]
2. Effects of One-Day Application of Levodopa/Carbidopa/Entacapone versus Levodopa/Carbidopa/Opicapone in Parkinson's Disease Patients.
Müller T; Schlegel E; Zingler S; Thiede HM
Cells; 2022 Apr; 11(9):. PubMed ID: 35563817
[TBL] [Abstract][Full Text] [Related]
3. Peripheral COMT inhibition prevents levodopa associated homocysteine increase.
Müller T; Muhlack S
J Neural Transm (Vienna); 2009 Oct; 116(10):1253-6. PubMed ID: 19657587
[TBL] [Abstract][Full Text] [Related]
4. Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations.
Rocha JF; Falcão A; Santos A; Pinto R; Lopes N; Nunes T; Wright LC; Vaz-da-Silva M; Soares-da-Silva P
Eur J Clin Pharmacol; 2014 Sep; 70(9):1059-71. PubMed ID: 24925090
[TBL] [Abstract][Full Text] [Related]
5. Tolcapone decreases plasma levels of S-adenosyl-L-homocysteine and homocysteine in treated Parkinson's disease patients.
Müller T; Kuhn W
Eur J Clin Pharmacol; 2006 Jun; 62(6):447-50. PubMed ID: 16758261
[TBL] [Abstract][Full Text] [Related]
6. Decrease of methionine and S-adenosylmethionine and increase of homocysteine in treated patients with Parkinson's disease.
Müller T; Woitalla D; Hauptmann B; Fowler B; Kuhn W
Neurosci Lett; 2001 Jul; 308(1):54-6. PubMed ID: 11445284
[TBL] [Abstract][Full Text] [Related]
7. Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.
Najib J
Clin Ther; 2001 Jun; 23(6):802-32; discussion 771. PubMed ID: 11440283
[TBL] [Abstract][Full Text] [Related]
8. Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR.
Paija O; Laine K; Kultalahti ER; Leinonen M; Huupponen R; Gordin A; Reinikainen K
Clin Neuropharmacol; 2005; 28(3):115-9. PubMed ID: 15965309
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of oral entacapone after frequent multiple dosing and effects on levodopa disposition.
Rouru J; Gordin A; Huupponen R; Huhtala S; Savontaus E; Korpela K; Reinikainen K; Scheinin M
Eur J Clin Pharmacol; 1999 Aug; 55(6):461-7. PubMed ID: 10492060
[TBL] [Abstract][Full Text] [Related]
10. The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats.
Nissinen E; Nissinen H; Larjonmaa H; Väänänen A; Helkamaa T; Reenilä I; Rauhala P
J Neural Transm (Vienna); 2005 Sep; 112(9):1213-21. PubMed ID: 15614425
[TBL] [Abstract][Full Text] [Related]
11. Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.
Ferreira JJ; Almeida L; Cunha L; Ticmeanu M; Rosa MM; Januário C; Mitu CE; Coelho M; Correia-Guedes L; Morgadinho A; Nunes T; Wright LC; Falcão A; Sampaio C; Soares-da-Silva P
Clin Neuropharmacol; 2008; 31(1):2-18. PubMed ID: 18303486
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic-pharmacodynamic interaction between nebicapone, a novel catechol-o-methyltransferase inhibitor, and controlled-release levodopa/carbidopa 200 mg/50 mg : randomized, double-blind, placebo-controlled, crossover study in healthy subjects.
Vaz-da-Silva M; Loureiro AI; Nunes T; Lopes C; Rocha J; Machado R; Costa R; Torrão L; Falcão A; Wright L; Almeida L; Soares-da-Silva P
Drugs R D; 2008; 9(6):435-46. PubMed ID: 18989992
[TBL] [Abstract][Full Text] [Related]
13. Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.
Muhlack S; Herrmann L; Salmen S; Müller T
J Neural Transm (Vienna); 2014 Nov; 121(11):1357-66. PubMed ID: 24770794
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.
Müller T; Erdmann C; Muhlack S; Bremen D; Przuntek H; Goetze O; Woitalla D
J Neural Transm (Vienna); 2006 Oct; 113(10):1441-8. PubMed ID: 16604302
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.
Nunes T; Machado R; Rocha JF; Fernandes-Lopes C; Costa R; Torrão L; Loureiro AI; Falcão A; Vaz-da-Silva M; Wright L; Almeida L; Soares-da-Silva P
Clin Ther; 2009 Oct; 31(10):2258-71. PubMed ID: 19922897
[TBL] [Abstract][Full Text] [Related]
16. Entacapone improves absorption of a coadministered salt in patients with Parkinson's disease.
Müller T; Woitalla D; Goetze O; Erdmann C
Mov Disord; 2008 Jul; 23(10):1458-61. PubMed ID: 18546331
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics and pharmacodynamics of levodopa/carbidopa cotherapies for Parkinson's disease.
Müller T
Expert Opin Drug Metab Toxicol; 2020 May; 16(5):403-414. PubMed ID: 32238065
[No Abstract] [Full Text] [Related]
18. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients.
Lamberti P; Zoccolella S; Iliceto G; Armenise E; Fraddosio A; de Mari M; Livrea P
Mov Disord; 2005 Jan; 20(1):69-72. PubMed ID: 15390046
[TBL] [Abstract][Full Text] [Related]
19. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
[TBL] [Abstract][Full Text] [Related]
20. The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.
Piccini P; Brooks DJ; Korpela K; Pavese N; Karlsson M; Gordin A
J Neurol Neurosurg Psychiatry; 2000 May; 68(5):589-94. PubMed ID: 10766888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
